Related Experiment Video

Updated: Jul 10, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation

Andrew E Schade1, Gary L Schieven, Robert Townsend

  • 1Experimental Hematology and Hematopoiesis Section, Taussig Cancer, Cleveland, OH 44195, USA.

Blood
|October 27, 2007
PubMed

Insights

Dasatinib inhibits T-cell receptor (TCR) signaling and T-cell responses without causing cell death. This drug, dasatinib, can enhance immunomodulation when combined with other agents.

Area of Science:

  • Immunology
  • Molecular Biology
  • Pharmacology

Background:

  • Src family kinases (SFK), particularly p56(Lck) (Lck), are crucial for T-cell receptor (TCR) signal transduction.
  • Dasatinib is an oral small molecule inhibitor targeting Abl and SFKs, including Lck.

Purpose of the Study:

  • To investigate dasatinib's potential as a novel immunomodulatory agent by targeting Lck in antigen-induced T-cell signaling.
  • To assess the effects of dasatinib on T-cell activation, proliferation, and cytokine production.

Main Methods:

  • Inhibition of T-cell receptor (TCR)-mediated signal transduction.
  • Assessment of cellular proliferation and cytokine production.
  • Evaluation of in vivo T-cell responses.
  • Combination therapy studies with cyclosporine A and rapamycin.

Main Results:

  • Dasatinib effectively inhibited TCR-mediated signal transduction, T-cell proliferation, cytokine production, and in vivo T-cell responses.
  • Inhibition by dasatinib was reversible and did not induce apoptosis, with responses restored by bypassing TCR signaling.
  • Interleukin-2 (IL-2)-mediated signaling and proliferation remained largely unaffected, indicating specificity for TCR signaling.
  • Combination of dasatinib with cyclosporine A or rapamycin resulted in significantly enhanced T-cell activation inhibition.

Conclusions:

  • Dasatinib offers a novel approach to immunomodulation through targeted inhibition of Lck within the TCR signaling pathway.
  • Dasatinib's reversible inhibition and specificity for TCR signaling suggest a favorable safety profile.
  • Combining dasatinib with existing immunomodulatory drugs may enhance efficacy and potentially reduce toxicity, offering a promising strategy for improved immunomodulation.

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: